Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Doxorubicin enhances the capacity of B cells to activate T cells in urothelial urinary bladder cancer
Karolinska Inst, Unit Immunol & Allergy, Dept Med, Stockholm, Sweden.
Karolinska Inst, Unit Immunol & Allergy, Dept Med, Stockholm, Sweden.
Karolinska Inst, Unit Immunol & Allergy, Dept Med, Stockholm, Sweden.
Umeå Univ Hosp, Dept Surg & Perioperat Sci Urol & Androl, Umeå, Sweden; Karolinska Inst, Stockholm South Gen Hosp, Dept Urol, Stockholm, Sweden.
Visa övriga samt affilieringar
2017 (Engelska)Ingår i: Clinical Immunology, ISSN 1521-6616, E-ISSN 1521-7035, Vol. 176, s. 63-70Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Cancer is currently treated by a combination of therapies, including chemotherapy which is believed to suppress the immune system. Combination of immunotherapy and chemotherapy correlates with improved survival but needs careful planning in order to achieve a synergistic effect. In this study, we have demonstrated that doxorubicin treatment of B cells resulted in increased expression of CD86 and concordantly increased CD4(+) T cell activation in the presence of superantigen, an effect that was inhibited by the addition of a CD86 blocking antibody. Furthermore, doxorubicin resulted in decreased expression of the anti-inflammatory cytokines IL-10 and TNF-alpha. Finally, B cells from urinary bladder cancer patients, treated with a neoadjuvant regiment containing doxorubicin, displayed increased CD86-expression. We conclude that doxorubicin induces CD86 expression on B cells and hence enhances their antigen-presenting ability in vitro, a finding verified in patients. Development of tailored time and dose schedules may increase the effectiveness of combining chemotherapy and immunotherapy.

Ort, förlag, år, upplaga, sidor
2017. Vol. 176, s. 63-70
Nyckelord [en]
Doxorubicin, B cells, Immunology, Urinary bladder cancer, Neoadjuvant chemotherapy, CD86
Nationell ämneskategori
Cancer och onkologi Urologi och njurmedicin
Identifikatorer
URN: urn:nbn:se:uu:diva-320835DOI: 10.1016/j.clim.2016.12.003ISI: 000396965200008PubMedID: 28025135OAI: oai:DiVA.org:uu-320835DiVA, id: diva2:1091453
Forskningsfinansiär
Cancerfonden, 4-837/2015Vetenskapsrådet, VLL-582631Karolinska Institutets ForskningsstiftelseTillgänglig från: 2017-04-26 Skapad: 2017-04-26 Senast uppdaterad: 2018-07-13Bibliografiskt granskad

Open Access i DiVA

Fulltext saknas i DiVA

Övriga länkar

Förlagets fulltextPubMed

Sök vidare i DiVA

Av författaren/redaktören
Holmström, BennyHansson, Johan
Av organisationen
UrologkirurgiCentrum för klinisk forskning, Gävleborg
I samma tidskrift
Clinical Immunology
Cancer och onkologiUrologi och njurmedicin

Sök vidare utanför DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 222 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf